Spruce Biosciences, Inc. financial data

Symbol
SPRB on Nasdaq
Location
611 Gateway Boulevard, Suite 740, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 472 % -14.8%
Debt-to-equity 30.8 % +4.8%
Return On Equity -62.1 % -13.3%
Return On Assets -47.5 % -12.1%
Operating Margin -609 % +17.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.3M shares +1.45%
Common Stock, Shares, Outstanding 41.3M shares +1.45%
Entity Public Float 75M USD +233%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 41.3M shares +1.45%
Weighted Average Number of Shares Outstanding, Diluted 41.3M shares +1.45%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 7.1M USD -1.4%
Research and Development Expense 36.1M USD -23.6%
General and Administrative Expense 14.3M USD +10.1%
Operating Income (Loss) -43.2M USD +18.3%
Net Income (Loss) Attributable to Parent -39.4M USD +19.7%
Earnings Per Share, Basic -0.93 USD/shares +37.6%
Earnings Per Share, Diluted -0.93 USD/shares +37.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.1M USD -39.2%
Cash, Cash Equivalents, and Short-term Investments 60.1M USD -44.4%
Accounts Receivable, after Allowance for Credit Loss, Current 15M USD
Other Assets, Current 860K USD +105%
Assets, Current 63.6M USD -42.8%
Property, Plant and Equipment, Net 127K USD
Operating Lease, Right-of-Use Asset 1.4M USD -5.34%
Other Assets, Noncurrent 531K USD -12.5%
Assets 65.1M USD -42.4%
Accounts Payable, Current 1.8M USD -42.9%
Accrued Liabilities, Current 7.74M USD
Liabilities, Current 11.9M USD -51%
Operating Lease, Liability, Noncurrent 950K USD
Other Liabilities, Noncurrent 273K USD +24.1%
Liabilities 13.5M USD -51.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -227M USD -21.1%
Stockholders' Equity Attributable to Parent 51.6M USD -39.5%
Liabilities and Equity 65.1M USD -42.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15M USD -26.9%
Net Cash Provided by (Used in) Financing Activities -227K USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 41.3M shares +1.45%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.1M USD -39.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 53K USD -1.85%
Deferred Tax Assets, Valuation Allowance 67.1M USD +33.3%
Deferred Tax Assets, Gross 67.4M USD +32.8%
Operating Lease, Liability 1.27M USD -9.29%
Depreciation 9K USD +80%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -39.4M USD +18.3%
Lessee, Operating Lease, Liability, to be Paid 1.5M USD -13.7%
Operating Lease, Liability, Current 251K USD +80.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 354K USD +3.81%
Lessee, Operating Lease, Liability, to be Paid, Year One 343K USD +37.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 232K USD -31.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 365K USD +3.99%
Deferred Tax Assets, Operating Loss Carryforwards 33.4M USD -1.39%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.24M USD +9.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 376K USD +3.87%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 21K USD +61.5%
Deferred Tax Assets, Net of Valuation Allowance 249K USD -36.8%
Share-based Payment Arrangement, Expense 5.61M USD +33.4%
Interest Expense 357K USD -29.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%